Dentons advises Enodia Therapeutics on a €20.7 million seed financing

Paris-Dentons advised Enodia Therapeutics, a France-based biotechnology company, on its €20.7 million seed financing round-the financing will be used to accelerate the rollout of its technology platform and reach key new development milestones.

The round was co-led by Elaia, Pfizer Ventures and Bpifrance (through its InnoBio investment strategy), with participation from Wallonie Entreprendre, Argobio Studio, MACSF, Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.

Built on research originating from the Institut Pasteur and created within Argobio, Enodia Therapeutics is a French biotech developing an innovative approach that combines small-molecule therapeutics with advances in generative artificial intelligence.

Dentons advised on all corporate aspects of the transaction, supporting Enodia Therapeutics throughout the structuring and execution of the financing.

The Dentons team was led by Olivia Guéguen (Partner), with Pierre-Marie Gallo (Counsel) and Lisa Morand (Associate).

This transaction further reflects Dentons' sustained track record in the biotech and deeptech sector, advising on fundraising transactions involving a broad range of French and international investors.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com